CLPT

ClearPoint Neuro completed the acquisition of Irras Holdings Inc. for $27.5 million on November 6, 2025, and released its Q3 2025 earnings. On March 17, 2026, the company reported its Q4 and full-year 2025 results, with Q4 earnings per share missing analysts' consensus estimates. In early 2026, the stock experienced pressure due to weaker 2026 financial guidance and uncertainty regarding the FDA's stance on gene therapies. On April 20, 2026, ClearPoint Neuro announced Canadian approval for its Neuro Navigation System. On April 22, 2026, the company announced FDA clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and its first clinical use. The stock experienced a 25% gain in the month preceding May 6, 2026. On May 8, 2026, Stifel reinstated its coverage of ClearPoint Neuro with a Buy rating and a target price of $16. ClearPoint Neuro's stock had decreased by 6.3% since January 1, 2026, as of May 9, 2026. The company is scheduled to announce its first-quarter 2026 results on May 13, 2026.